Mobotinib side effects and how to deal with them

Mobotinib, as a targeted therapy drug, has shown significant efficacy in the treatment of non-small cell lung cancer (NSCLC), but it also has some side effects. Understanding these side effects and how to manage them is critical to the patient's treatment journey.

1. Common side effects

Nausea and vomiting: This is a common gastrointestinal reaction of mobotinib with a high incidence. Patients may experience nausea or even vomiting during treatment.

Diarrhea: Diarrhea is another common gastrointestinal side effect. About93% of patients may experience diarrhea during treatment.

Rash and itching: Some patients may develop rash and skin itching after taking mobotinib, which may be related to skin irritation from the drug.

Heart problems: Mobotinib may causeQTc interval prolongation, an electrocardiogram change that may increase the risk of arrhythmia.

Interstitial lung disease: Mobotinib may cause interstitial lung disease, or inflammation of the lungs, which is a serious side effect that can be life-threatening.

2. Treatment method

Nausea and vomiting: Patients can report these symptoms to their doctor, who can provide antiemetic drugs such as ondansetron to help relieve symptoms. Also, avoiding strong, pungent smells or foods may help reduce feelings of nausea.

Diarrhea: Symptoms of diarrhea can be relieved by adjusting your diet and eating low-fiber, easily digestible foods. If the diarrhea is severe, you may need to temporarily stop taking the medication and use antidiarrheal drugs under the guidance of a doctor.

Rash and itching: Patients should avoid scratching their skin to prevent infection. Your doctor may recommend allergy medications or topical medications to relieve symptoms.

Heart problems: Before starting treatment and during treatment, patients should have regular electrocardiograms to monitor heart function. If signs or symptoms of QTc prolongation associated with life-threatening arrhythmias occur, mobotinib should be permanently discontinued.

Interstitial Lung Disease: If new or progressive unexplained pulmonary symptoms occur (eg, dyspnea, cough, and fever), mobotinib therapy should be suspended immediately and diagnostic evaluation should be performed. If interstitial lung disease/pulmonary inflammation is diagnosed, this product should be permanently discontinued.

In short, when using mobotinib to treat non-small cell lung cancer, patients should pay close attention to their body's reaction and report any discomfort symptoms to their doctor in a timely manner. Through reasonable treatment and intervention, the impact of side effects on the treatment process can be reduced.